Exact Sciences announced recently the launch of Cancerguard, a multi-cancer early detection (MCED) blood test that is now available as a laboratory-developed test (LDT) in the United States.

According to a release, Cancerguard can detect more than 50 cancer types and subtypes and is the only MCED test on the market to analyze multiple biomarker classes, enhancing early cancer detection.

“Cancerguard builds on the legacy of Cologuard, which has delivered more than 20 million test results and transformed colorectal cancer screening,” Exact Sciences CEO and Chairman Kevin Conroy said in a statement. “Backed by strong science and developed to screen for many of the deadliest cancers, the Cancerguard test represents the next bold step in our mission to detect cancer earlier.”

Cancerguard is priced at $689 and may be eligible for flexible spending and health savings account use.

The test will be available broadly via telehealth starting in October.